Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia

Hematology

Volumn 13, Issue 3, 2008, Pages 142-146

  Jeddi, Ramzi ^a   Kacem, Karima ^a   Neji, Hend Ben ^a   Mnif, Samia ^b   Gouider, Emna ^a   Aissaoui, Lamia ^a   Amor, Ramzi Ben ^a   Lakhal, Raihane Ben ^a   Abid, Hela Ben ^a   Belhadjali, Zaher ^a   Meddeb, Balkis ^a  

^a Hopital Aziza Othmana   (Tunisia)

^b PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

APL; ATRA; Complications; Induction

Indexed keywords

CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; IDARUBICIN; PREDNISONE; RETINOIC ACID;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGE; ARTICLE; BODY MASS; BRAIN PSEUDOTUMOR; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; GENDER; HUMAN; LEUKOCYTE COUNT; MALE; PERINEUM INJURY; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RESPIRATORY DISTRESS; RETINOIC ACID SYNDROME; RISK FACTOR; SCHOOL CHILD; SCROTUM DISORDER; TUNISIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN;

EID: 55849110808     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X316112     Document Type: Article

References (26)

1. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and-ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia, The European APL Group. Blood 1999; 14: 1192-1200.
2. Sanz MA, Martin G, Gonzalez M et al. Risk adapted treatment of acute promyelocytic leukemia with all Trans retinoic acid and anthracycline monochemotherapy: A-multicenter study by the PETHEMA group. Blood 2004; 103 (9): 1237-1243.
3. Sanz MA, Martin G, Rayon C et al. A modified AIDA protocol with anthracyclin based consolidation result in high anti leukemia efficacy and reduced toxicity in newly diagnosed PMl/RARalpha positive acute promyelocytic leukemia PETHEMA group. Blood 1999; 94: 3015-3021.
4. Tallman MS, Andersen JW, Schiffer CA et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 90-95.
5. De Botton S, Dombret H, Sanz M et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712-2727.
6. Simzar S, Rotunda AM, Craft N. Scrotal ulceration as a consequence of all-trans-retinoic acid (ATRA) for the treatment of acute promyelocytic, leukemia. Drugs Dermatol, 2005; 4: 231-232.
7. Frankel, SR, Eardley A, Heller G et al. All-trans retinoic acid for acute promyelocyic leukemia. Results of the New York study. Ann Intern Med, 1994; 120: 278-286.
8. Vahdat L, Maslak P, Miller Jr WH et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
9. Von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol, 1994; 45: 861-865.
10. Friedman DI. Idiopathic intracranial hypertension. Curr Pain Headache Rep 2007; 11 (1): 62-68.
11. Cheson BD, Cassileth PA, Head DR et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
12. Dan Dower. The epidemiology of acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 357-367.
13. Cartwright RA. Leukemia. In: Whittaker JA (ed). Epidemiology. 2nd ed. Oxford: Blackwell Scientific Publications; 1995, 3-33.
14. Avvisati G, Mele A, Stasi MA et al. Epidemiology of acute promyelocytc: Leukemia in Italy. APL Collaborating Group. Ann Oncol 1991; 2: 405-408.
15. Mele A, Stasi MA, Pulsoni A et al. Epidemiology of acute promyelocytic leukemia. Haematologica 1995; 80: 405-408
16. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92; 2322-2333.
17. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997; 11: 1661-1664.
18. Melnick A, Licht JD. Deconstructing a disease: RAR alpha, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukaemia. Blood 1998; 93: 3167-3215.
19. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780-2786.
20. Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocrine Rev 2006; 27: 449-467.
21. konopleva M, Mikhail A, Estov Z et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: Proliferative and anti-apoptic activities. Blood 1999; 93: 1668-1676.
22. Tabe Y, Konopleva M, Munsell MF et al. PML-RAR-α is associated with leptin-receptor induction: The role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004; 103: 1815-1822.
23. Cohen PR. Sweet's syndrome-a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2: 34.
24. Lampl Y, Eshel Y, Kessler A et al. Serum leptin level in women with idiopathic intracranial hypertension. Neurol Neuros Psych 2002; 72: 642-643.
25. Thompson DF, Montarella KE. Drug-induced Sweet's syndrome. Ann Pharmacotherapy 2007; 41: 802-811.
26. Pollack A. Handbook of essential drugs and regimens in hematological oncology. New York: Harwood Academic Publishers; 1991, 33-34.